Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

Riten Kumar, Paul J. Galardy, Ahmet Dogan, Vilmarie Rodriguez, Shakila P. Khan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

Original languageEnglish (US)
Pages (from-to)317-320
Number of pages4
JournalPediatric Blood and Cancer
Volume57
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Follicular Lymphoma
Pediatrics
Drug Therapy
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Rituximab
Therapeutics

Keywords

  • Follicular lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. / Kumar, Riten; Galardy, Paul J.; Dogan, Ahmet; Rodriguez, Vilmarie; Khan, Shakila P.

In: Pediatric Blood and Cancer, Vol. 57, No. 2, 08.2011, p. 317-320.

Research output: Contribution to journalArticle

Kumar, R, Galardy, PJ, Dogan, A, Rodriguez, V & Khan, SP 2011, 'Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma', Pediatric Blood and Cancer, vol. 57, no. 2, pp. 317-320. https://doi.org/10.1002/pbc.23110
Kumar, Riten ; Galardy, Paul J. ; Dogan, Ahmet ; Rodriguez, Vilmarie ; Khan, Shakila P. / Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 2. pp. 317-320.
@article{85c0fb148fd0490d8e747688f1c9c38a,
title = "Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma",
abstract = "Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.",
keywords = "Follicular lymphoma, Rituximab",
author = "Riten Kumar and Galardy, {Paul J.} and Ahmet Dogan and Vilmarie Rodriguez and Khan, {Shakila P.}",
year = "2011",
month = "8",
doi = "10.1002/pbc.23110",
language = "English (US)",
volume = "57",
pages = "317--320",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma

AU - Kumar, Riten

AU - Galardy, Paul J.

AU - Dogan, Ahmet

AU - Rodriguez, Vilmarie

AU - Khan, Shakila P.

PY - 2011/8

Y1 - 2011/8

N2 - Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

AB - Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations. Herein, we report our institutional experience of using rituximab with multiagent chemotherapy for pediatric FL. Six pediatric patients were diagnosed with FL from 2000 to 2009. All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations. Five of the six patients remain in remission with a median follow-up of 31 months. Larger randomized trials are indicated to establish the efficacy of this regimen for pediatric FL patients.

KW - Follicular lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79958782287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958782287&partnerID=8YFLogxK

U2 - 10.1002/pbc.23110

DO - 10.1002/pbc.23110

M3 - Article

VL - 57

SP - 317

EP - 320

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -